BR112013030169A2 - métodos de tratamento de esclerose múltipla e preservação e/ou aumento do teor de mielina - Google Patents

métodos de tratamento de esclerose múltipla e preservação e/ou aumento do teor de mielina

Info

Publication number
BR112013030169A2
BR112013030169A2 BR112013030169A BR112013030169A BR112013030169A2 BR 112013030169 A2 BR112013030169 A2 BR 112013030169A2 BR 112013030169 A BR112013030169 A BR 112013030169A BR 112013030169 A BR112013030169 A BR 112013030169A BR 112013030169 A2 BR112013030169 A2 BR 112013030169A2
Authority
BR
Brazil
Prior art keywords
reducing
multiple sclerosis
methods
fumarate
myelin content
Prior art date
Application number
BR112013030169A
Other languages
English (en)
Portuguese (pt)
Inventor
Alfred Sandrock
Gilmore O'neill
Katherine Dawson
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47217796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013030169(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of BR112013030169A2 publication Critical patent/BR112013030169A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013030169A 2011-05-26 2012-05-25 métodos de tratamento de esclerose múltipla e preservação e/ou aumento do teor de mielina BR112013030169A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490572P 2011-05-26 2011-05-26
US201261625624P 2012-04-17 2012-04-17
PCT/US2012/039721 WO2012162669A1 (en) 2011-05-26 2012-05-25 Methods of treating multiple sclerosis and preserving and/or increasing myelin content

Publications (1)

Publication Number Publication Date
BR112013030169A2 true BR112013030169A2 (pt) 2016-08-09

Family

ID=47217796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013030169A BR112013030169A2 (pt) 2011-05-26 2012-05-25 métodos de tratamento de esclerose múltipla e preservação e/ou aumento do teor de mielina

Country Status (19)

Country Link
US (1) US20140163100A1 (https=)
EP (1) EP2713724A4 (https=)
JP (1) JP2014515373A (https=)
KR (1) KR20140036257A (https=)
CN (1) CN103732062A (https=)
AU (1) AU2012258558A1 (https=)
BR (1) BR112013030169A2 (https=)
CA (1) CA2836480A1 (https=)
CL (1) CL2013003358A1 (https=)
CO (1) CO6811862A2 (https=)
EA (1) EA201391578A1 (https=)
EC (1) ECSP13013117A (https=)
IL (1) IL229448A0 (https=)
MX (1) MX2013013781A (https=)
PE (1) PE20141316A1 (https=)
PH (1) PH12013502443A1 (https=)
SG (1) SG195049A1 (https=)
WO (1) WO2012162669A1 (https=)
ZA (1) ZA201308681B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526586C (en) 2003-09-09 2010-03-16 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
PL2316430T3 (pl) 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
RU2554347C2 (ru) 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
KR20150080037A (ko) 2011-06-08 2015-07-08 바이오젠 엠에이 인코포레이티드 고순도 및 결정질 다이메틸 푸마레이트의 제조 방법
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
CA2882730C (en) 2012-08-22 2019-12-31 Arbor Pharmaceuticals, Llc Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
WO2014031901A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of use for monomethyl fumarate and prodrugs thereof
EP2934503B1 (en) 2012-12-21 2019-04-10 Biogen MA Inc. Deuterium substituted fumarate derivatives
KR102085557B1 (ko) 2013-03-14 2020-03-06 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
CN103724198A (zh) * 2013-11-28 2014-04-16 镇江圣安医药有限公司 富马酸二甲酯的新型衍生物及其应用
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
ES2713157T3 (es) 2014-02-28 2019-05-20 Banner Life Sciences Llc Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
JP6564868B2 (ja) * 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
MA40985A (fr) * 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
KR20200013086A (ko) 2014-12-11 2020-02-05 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
ES2599227T3 (es) * 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
EP2680010A1 (en) * 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
RU2554347C2 (ru) * 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
JP2012525385A (ja) * 2009-04-29 2012-10-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経変性および神経炎症の治療

Also Published As

Publication number Publication date
ZA201308681B (en) 2017-11-29
MX2013013781A (es) 2014-01-08
SG195049A1 (en) 2013-12-30
EA201391578A1 (ru) 2014-05-30
IL229448A0 (en) 2014-01-30
CN103732062A (zh) 2014-04-16
CA2836480A1 (en) 2012-11-29
US20140163100A1 (en) 2014-06-12
EP2713724A4 (en) 2015-03-11
ECSP13013117A (es) 2014-06-30
PE20141316A1 (es) 2014-10-01
PH12013502443A1 (en) 2019-03-22
CL2013003358A1 (es) 2014-08-01
CO6811862A2 (es) 2013-12-16
WO2012162669A1 (en) 2012-11-29
EP2713724A1 (en) 2014-04-09
JP2014515373A (ja) 2014-06-30
KR20140036257A (ko) 2014-03-25
AU2012258558A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
BR112013030169A2 (pt) métodos de tratamento de esclerose múltipla e preservação e/ou aumento do teor de mielina
PH12020500352A1 (en) Therapeutic uses of empagliflozin
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112012024349A2 (pt) métodos de tratamento de carcinoma hepatocelular
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
MX2013011922A (es) Compuestos de benceno substituido.
MX378422B (es) Uso de empagliflozina para el tratamiento de trastornos metabòlicos, la prevenciòn, y para la reducciòn del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MY162903A (en) Methods of treatment of pancreatic cancer
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
PH12013502118A1 (en) Aryl-or heteroaryl-substituted benzene compounds
BR112015006055A2 (pt) composições e métodos para o tratamento e prevenção de lesão tecidual e doença
MY166036A (en) Methods of treating pain
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
BR112014010729A2 (pt) métodos para tratamento de ataques de gota
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
BR112013007423A2 (pt) terapia combinada no que diz respeito ao tratamento da infecção por hcv
BR112012019921A2 (pt) composições líquidas compreendendo um agente de resfriamento não-metol e um espessante para tratamento de um sintoma respiratório.
NZ700546A (en) Use of neuregulin to treat peripheral nerve injury
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.
BR112015020261A2 (pt) composições farmacêuticas de dexmetilfenidato ou sais do mesmo de liberação modificada
MX337139B (es) Composicion de miel con l-alanil-l-glutamina.
BR112013020195A2 (pt) composições farmacêuticas livres de citrato compreendendo anakinra
BR112016006582A2 (pt) terapia combinada laquinimod para o tratamento da esclerose múltipla
BR112014015193A2 (pt) composição enriquecida com glicoproteína como um aditivo para alimento e/ou ração e/ou como um agente terapêutico

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOGEN MA INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]